Monitor for stockholder vote on the 19.99% issuance cap and any subsequent conversion notices from holders. The $4.00 floor price provides a downside cushion for conversion, but if PMI trades below $4.00, holders may still convert at $4.00, creating immediate dilution. Watch for any equity financing ≥$10M that would trigger a forced company conversion.
Price Chart
Executive Summary
Picard Medical issued $1.0 million aggregate principal amount of 3% unsecured convertible notes to three accredited investors on September 30, 2026. The notes mature on September 30, 2027, are convertible at a floor price of $4.00 per share, and each conversion share comes with a pre-funded warrant exercisable at $0.0001 per share. This financing provides near-term cash but creates significant potential dilution of up to 500,000 shares (250,000 common shares plus 250,000 pre-funded warrants) and signals the company is raising capital via dilutive debt rather than operating cash flow.
Key Financial Metrics
Key Facts
- Issued $1.0 million aggregate principal amount of 3% unsecured convertible notes to three accredited investors on September 30, 2026.
- Notes mature on September 30, 2027; conversion floor price is $4.00 per share.
- Conversion of the full $1.0 million at the $4.00 floor price yields up to 250,000 common shares plus 250,000 pre-funded warrants (exercisable at $0.0001/share).
- Company may force conversion upon an equity financing of at least $10.0 million in gross proceeds.
- Issuance is capped at 19.99% of outstanding shares until stockholder approval is obtained.
- The notes are unsecured and bear interest at 3% per annum.
Financial Impact
Up to 500,000 shares of dilution (250,000 common + 250,000 pre-funded warrants) on a $1.0 million principal; potential dilution of ~19.99% of current outstanding shares before stockholder approval.
Risk Factors
- Significant dilution risk: up to 500,000 shares issuable upon full conversion and warrant exercise.
- Low 3% interest rate suggests distressed financing terms; unsecured status increases credit risk.
- Pre-funded warrants at $0.0001/share are nearly in-the-money immediately, adding overhang.
- Company may need stockholder approval to issue beyond 19.99% of outstanding shares.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032125 |
| Exhibit: ex_1021858.htm | 0001437749-26-032125 |
| Document: pmi20260916_8k.htm | 0001437749-26-032125 |
| Document: 0001437749-26-032125-index-headers.html | 0001437749-26-032125 |
| Document: 0001437749-26-032125-index.html | 0001437749-26-032125 |
| Document: 0001437749-26-032125.txt | 0001437749-26-032125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $6.43 | awaiting T+60 | — | $6.83 (+6.22%) |
Oct 22, 2026 5d ago | S-3 | $7.37 | awaiting T+60 | — | $6.83 (+7.33%) |
Oct 6, 2026 21d ago | 8-K | $8.74 | awaiting T+60 | — | $6.83 (+21.85%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.83 (+7679.04%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.83 (+4168.75%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.83 (+4453.33%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.83 (+3931.88%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.83 (+4281.01%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.83 (−49.41%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.83 (+49.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers